PN6047 / PharmNovo - LARVOL DELTA

Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain (GlobeNewswire) - "The trial will be initiated in Spain, but PharmNovo plans to also submit applications to expand the study to Czech Republic and Poland. Provided that the necessary funding for the implementation of the study is secured, patient enrolment is expected to start by mid-2026."

New P2a trial • Pain